Drug · DIN 02246554
REMODULIN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 7, 2005; first marketed April 30, 2004.
- Drug Identification Number (DIN)
- 02246554
- Company (DIN owner)
- United Therapeutics CorporationDurham, North Carolina, United States
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Intravenous; Subcutaneous
- Therapeutic class (ATC)
- Treprostinil B01AC21
- Class
- Human
- Record last updated
- June 25, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TREPROSTINIL (TREPROSTINIL SODIUM) | 5 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 6, 2005: NOC 7533Supplement to a New Drug Submission (SNDS) · New route of administration - intravenous
- October 4, 2002: NOC 833New Drug Submission (NDS)
Other DINs named REMODULIN
- DIN 02246552 · Marketed
- DIN 02246553 · Marketed
- DIN 02246555 · Marketed